Serum lipids and the progression of nephropathy in type 1 diabetes

被引:55
作者
Thomas, MC
Rosengård-Bärlund, M
Mills, V
Rönnback, M
Thomas, S
Forsblom, C
Cooper, ME
Taskinen, MR
Viberti, G
Groop, PH
机构
[1] Baker Heart Res Inst, Melbourne, Vic, Australia
[2] Univ Helsinki, Cent Hosp, Div Nephrol, Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Div Cardiol, Helsinki, Finland
[4] Univ London Kings Coll, Guys Hosp, Div Cardiovasc, London WC2R 2LS, England
关键词
D O I
10.2337/diacare.29.02.06.dc05-0809
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Dyslipidemia contributes to the progression of microvascular disease in diabetes. However, different lipid variables may be important at different stages of nephropathy. This study examines the pattern of dyslipidemia associated with the progression of nephropathy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS - A total of 152 patients with type 1 diabetes were recruited in order to represent various phases of nephropathy. Patients were followed for 8-9 years, during which time they received standard care. Renal progression was defined a priori as a doubling in albumin excretion.(in patients with normo- or microalbuminuria) or a decline in creatinine clearance (in those with macroalbuminuria). A panel of lipid variables was determined and correlated with indexes of progression. RESULTS - in patients with normoalbuminuria (n = 66), progression was associated with male sex (P < 0.05), borderline albuminuria (P = 0.02), and LDL-free cholesterol (P = 0.02). In patients with microalbuminuria (it = 51), progression was independently associated with triglyceride content of VLDL and intermediate-density lipoprotein (both P < 0.05). In patients with macroalbuminuria (n = 36), a significant decline in the renal function (> 3 ml (.) min(-1.) year(-1)) was independently associated with poor glycemic control, hypertension, and LDL size (P < 0.05). When all patients with progressive nephropathy were analyzed together, only LDL cholesterol was predictive on multivariate analysis (P < 0.05), which masked the importance of triglyceride enrichment in microalbuminuria. CONCLUSIONS - Lipid variables are associated with progression of diabetic kidney disease, but the relationship is not the same at all stages. This finding has implications for the design of renoprotective strategies and the interpretation of clinical trials in type 1 diabetes.
引用
收藏
页码:317 / 322
页数:6
相关论文
共 27 条
[1]  
ANTIKAINEN M, 1992, CLIN NEPHROL, V38, P254
[2]   Cardiovascular outcomes among participants with diabetes in the recent large statin trials [J].
Armitage, J ;
Bowman, L .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (04) :439-446
[3]  
Bonnet F, 2000, DIABETES METAB, V26, P254
[4]  
Bucala R, 1996, NEPHROL DIAL TRANSPL, V11, P17
[5]   Risk factors for renal failure: The WHO multinational study of vascular disease in diabetes [J].
Colhoun, HM ;
Lee, ET ;
Bennett, PH ;
Lu, M ;
Keen, H ;
Wang, SL ;
Stevens, LK ;
Fuller, JH .
DIABETOLOGIA, 2001, 44 (Suppl 2) :S46-S53
[6]  
Collins R, 2003, LANCET, V361, P2005
[7]   PREDICTORS OF MICROALBUMINURIA IN INDIVIDUALS WITH IDDM [J].
COONROD, BA ;
ELLIS, D ;
BECKER, DJ ;
BUNKER, CH ;
KELSEY, SF ;
LLOYD, CE ;
DRASH, AL ;
KULLER, LH ;
ORCHARD, TJ .
DIABETES CARE, 1993, 16 (10) :1376-1383
[8]   Lipid modulation in insulin-dependent diabetes mellitus - Effect on microvascular outcomes [J].
Fried, LF ;
Forrest, KYZ ;
Ellis, D ;
Chang, YF ;
Silvers, N ;
Orchard, TJ .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2001, 15 (03) :113-119
[9]   Multiple lipoprotein abnormalities in type I diabetic patients with renal disease [J].
Groop, PH ;
Elliott, T ;
Ekstrand, A ;
FranssilaKallunki, A ;
Friedman, R ;
Viberti, GC ;
Taskinen, MR .
DIABETES, 1996, 45 (07) :974-979
[10]   LIPOPROTEIN(A) IN TYPE-1 DIABETIC-PATIENTS WITH RENAL-DISEASE [J].
GROOP, PH ;
VIBERTI, GC ;
ELLIOTT, TG ;
FRIEDMAN, R ;
MACKIE, A ;
EHNHOLM, C ;
JAUHIAINEN, M ;
TASKINEN, MR .
DIABETIC MEDICINE, 1994, 11 (10) :961-967